dc.contributor.author | DiPaola, Frank | |
dc.contributor.author | Oral, Elif A. | |
dc.contributor.author | Neidert, Adam H. | |
dc.contributor.author | Westerhoff, Maria | |
dc.contributor.author | Taylor, Simeon | |
dc.contributor.author | Akinci, Baris | |
dc.contributor.author | Meral, Rasimcan | |
dc.contributor.author | Rus, Diana | |
dc.contributor.author | Hench, Rita | |
dc.date.accessioned | 2021-12-10T09:50:07Z | |
dc.date.available | 2021-12-10T09:50:07Z | |
dc.identifier.citation | Akinci B., Meral R., Rus D., Hench R., Neidert A. H. , DiPaola F., Westerhoff M., Taylor S., Oral E. A. , "The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide", ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2020 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_15afd136-e238-4a7b-b142-67ae4253f37e | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/168588 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/15afd136-e238-4a7b-b142-67ae4253f37e/file | |
dc.identifier.uri | https://doi.org/10.1530/edm-19-0139 | |
dc.description.abstract | A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared. Because her metabolic status continued to deteriorate, a therapeutic trial with melanocortin-4 receptor agonist setmelanotide, that is believed to function downstream from leptin receptor in the leptin signaling system, was undertaken in an effort to improve her metabolic status for the first time in a patient with lipodystrophy. To achieve this, a compassionate use (investigational new drug application; IND) was initiated (NCT03262610). Glucose control, body fat by dual-energy X-ray absorptiometry and MRI, and liver fat by proton density fat fraction were monitored. Daily hunger scores were assessed by patient filled questionnaires. Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired. Targeting melanocortin-4 receptor to regulate energy metabolism in this setting was not sufficient to obtain a significant metabolic benefit. However, complex features of our case make it difficult to generalize these observations to all cases of lipodystrophy. It is still possible that melanocortin-4 receptor agonistic action may offer some therapeutic benefits in leptin-deficient patients. | |
dc.language.iso | eng | |
dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
dc.subject | Endocrinology | |
dc.subject | Endocrine and Autonomic Systems | |
dc.subject | Endocrinology, Diabetes and Metabolism | |
dc.subject | Life Sciences | |
dc.subject | Health Sciences | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
dc.title | The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide | |
dc.type | Makale | |
dc.relation.journal | ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS | |
dc.contributor.department | University of Michigan System , , | |
dc.contributor.firstauthorID | 2633768 | |